MK0941 free base · Synonyms: MK-0941 · MK 0941

MK-0941 is a selective, orally active, and allosteric glucokinase activator.

For research use only. Not for human or veterinary use.

Target Glucokinase

Research area Metabolic Disease

Purity >98% Stock Inquire

Data Sheet SDS COA

MK0941 structure

CAS No.: 1137916-97-2

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 498.00	BP-02505-50mg	In stock	Get quote
100 mg	USD 797.00	BP-02505-100mg	In stock	Get quote
250 mg	USD 1,398.00	BP-02505-250mg	In stock	Get quote
500 mg	USD 2,398.00	BP-02505-500mg	In stock	Get quote
1 g	Inquire	BP-02505-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

MK-0941 is a selective, orally active, and allosteric glucokinase activator with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 activates hexokinase subtype IV. MK-0941 can increase insulin secretion and glucose uptake. MK-0941 can be studied in research for type 2 diabetes .

Biological activity

MK-0941 is a potent, orally active and allosteric glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 has potential in the treatment of type 2 diabetes.

Identifiers

SMILES: CS(O)(=O)=O.CCS(=O)(=O)C1=NC=C(OC2=CC(O[C@@H](C)CO)=CC(=C2)C(=O)NC2=NN(C)C=C2)C=C1
InChIKey: PIDNRTWDGDJKSQ-UQKRIMTDSA-N

Specifications

MW (average): 556.6090
Formula: C₂₂H₂₈N₄O₉S₂
CAS No.: 1137916-97-2
Physical state: Solid
Color: White to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4°C, sealed storage, away from moisture

Solubility

Soluble in DMSO

Documents

References

[1]. Eiki J, et al. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol. 2011 Dec;80(6):1156-65.

[2]. Meininger, G. E., et al., (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes care, 34(12), 2560–2566.

Same research area

Search Metabolic Disease